Benedetti Francesco, Barbini Barbara, Fulgosi Mara Cigala, Colombo Cristina, Dallaspezia Sara, Pontiggia Adriana, Smeraldi Enrico
Department of Neuropsychiatric Sciences, Scientific Institute and University Vita-Salute San Raffaele, San Raffaele Turro, Via Stamira d'Ancona 20, Milan, Italy.
J Clin Psychiatry. 2005 Dec;66(12):1535-40. doi: 10.4088/jcp.v66n1207.
Drug resistance remains a persistent source of morbidity and mortality for patients with bipolar depression. A growing number of clinical studies support the usefulness of chronotherapeutic interventions, such as total sleep deprivation (TSD) and light therapy (LT), in the treatment of nonresistant bipolar depression.
To investigate the clinical usefulness of TSD plus LT in the treatment of drug-resistant bipolar depression, we treated 60 inpatients for 1 week with repeated TSD and LT combined with ongoing antidepressants and lithium salts. All patients had a DSM-IV diagnosis of bipolar I disorder. Drug resistance was rated according to Thase and Rush criteria. The pattern of relapses and recurrences was assessed during a prospective 9-month follow-up. Data were gathered from September 2002 to July 2004.
A 2-way repeated-measures analysis of variance with changes in self-rated perceived mood scores as dependent variable and with time and group (history of drug resistance) as independent factors confirmed significant time-by-group interaction (p = .0339). A logistic regression on rates of achievement of response (50% reduction in Hamilton Rating Scale for Depression ratings) confirmed the significance of observed differences: overall, 70% (23/33) of nonresistant versus 44% (12/27) of drug-resistant patients achieved response (p = .045). A survival time analysis (Cox proportional hazards model) showed that history of drug resistance significantly influenced the pattern of relapses and recurrences, with 57% (13/23) of nonresistant responders and 17% (2/12) of drug-resistant responders being euthymic after 9 months (p = .0212).
The combination of repeated TSD and LT in drug-resistant patients was useful in triggering an acute response. Further clinical research is needed to optimize this treatment option for drug-resistant patients in the long term.
耐药性仍是双相抑郁症患者发病和死亡的持续原因。越来越多的临床研究支持时间治疗干预措施,如完全睡眠剥夺(TSD)和光疗法(LT),在治疗非耐药性双相抑郁症中的有效性。
为了研究TSD联合LT治疗耐药性双相抑郁症的临床有效性,我们对60名住院患者进行了为期1周的治疗,采用重复TSD和LT并联合使用抗抑郁药和锂盐。所有患者均符合DSM-IV双相I型障碍的诊断标准。根据Thase和Rush标准评定耐药性。在前瞻性9个月的随访期间评估复发和再发模式。数据收集于2002年9月至2004年7月。
以自评情绪评分变化为因变量、时间和组(耐药史)为自变量的双向重复测量方差分析证实了显著的时间×组交互作用(p = 0.0339)。对缓解率(汉密尔顿抑郁量表评分降低50%)进行的逻辑回归证实了观察到的差异的显著性:总体而言,非耐药患者中有70%(23/33)达到缓解,而耐药患者中有44%(12/27)达到缓解(p = 0.045)。生存时间分析(Cox比例风险模型)表明,耐药史显著影响复发和再发模式,9个月后,非耐药缓解者中有57%(13/23)心境正常,而耐药缓解者中有17%(2/12)心境正常(p = 0.0212)。
在耐药患者中,重复TSD和LT的联合使用有助于引发急性反应。需要进一步的临床研究来长期优化这种针对耐药患者的治疗方案。